(Q36728599)

15 August 2017

1 reference

title

Gene therapy progress and prospects: RNA aptamers (English)

1 reference

15 August 2017

0 references

Que-Gewirth NS

1

1 reference

15 August 2017

Sullenger BA

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 February 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

14

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

283-291

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302900

15 August 2017

exact match

0 references

cites work

Aptamers: an emerging class of therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamers against extracellular targets for in vivo applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Crystal structure of NF- B (p50)2 complexed to a high-affinity RNA aptamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Direct in vitro selection of a 2'-O-methyl aptamer to VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Pharmacokinetics and biodistribution of novel aptamer compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Perspective in progress of cardiovascular gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Application of decoy oligodeoxynucleotides-based approach to renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Transcription factor decoys: a new model for disease intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Oligo oligarchy-the surprisingly small world of aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Light regulation of aptamer activity: an anti-thrombin aptamer with caged thymidine nucleobases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

HIV-1 inactivation by nucleic acid aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Gene therapy progress and prospects: novel gene therapy approaches for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

RNA-mediated inhibition of HIV in a gene therapy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Inhibition of HCV NS3 protease by RNA aptamers in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Lentiviral-mediated delivery of siRNAs for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Strategies for retargeted gene delivery using vectors derived from lentiviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Nanoparticle-aptamer bioconjugates for cancer targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamer:toxin conjugates that specifically target prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Partnering aptamer and RNAi technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Deconvolution of a complex target using DNA aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamers evolved from live cells as effective molecular probes for cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamers as tools for target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Aptamers--basic research, drug development, and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

Antidote-mediated control of an anticoagulant aptamer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

Light-induced formation of G-quadruplex DNA secondary structures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

An anticoagulant with light-triggered antidote activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302900

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302900

1 reference

15 August 2017

1 reference